FDA Expands Indication For Revlimid
February 18, 2015 at 12:40 PM EST
Celgene today announced that the FDA has expanded the existing indication for Revlimid® (lenalidomide) in combination with dexamethasone to include patients newly diagnosed with multiple myeloma.
